KRAS and cancer: Consequently, kinases and TFs often accumulate cancer driver mutations, such as TP53 (Rivlin et al, 2011) and KRAS (Wang et al, 2015), and are the targets of anti‐cancer drugs (Bhagwat & Vakoc, 2015; Bhullar et al, 2018).